Results 91 to 100 of about 56,774 (264)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients

Journal of Central Nervous System Disease, 2011
Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this
James J. Marriott
doaj   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Usage of Multimodal Evoked Potentials in Diagnosis of Changes in Central Nervous System in Multiple Sclerosis

Türk Nöroloji Dergisi, 2011
OBJECTIVE: Evoked potentials are used in the functional assessment of sensory and motor pathways. Conflicting results have been reported in different studies about the value of evoked potentials in demyelinating diseases.
Bahar Özbek, Kemal Balcı, Yahya Çelik
doaj   +2 more sources

Epidemiology of Multiple Sclerosis in Fars Province

مجله اپیدمیولوژی ایران, 2014
Background & Objectives : Multiple Sclerosis is a chronic progressive disease with several disabilities for patients. Its distribution in the world can be an important clue to study racial, genetic, and environmental factors; thus, epidemiologic studies ...
S Izadi, AR Nikseresht, M Poursadeghfard
doaj  

New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals

Frontiers in Immunology
The onset and relapse of autoimmune diseases (AIDs) are triggered by autoimmune attacks on target tissues. However, symptoms are unlikely to appear if damaged cells are rapidly replaced.
Zeev Elkoshi
doaj   +1 more source

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Therapeutic Advances in Neurological Disorders, 2016
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing.
Bhupendra O. Khatri
doaj   +1 more source

Group sequential designs for negative binomial outcomes

, 2018
Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of ...
Friede, Tim, Glimm, Ekkehard, Mütze, Tobias, Schmidli, Heinz   +3 more
core   +1 more source

Epilepsy syndromes classification

Epilepsia Open, EarlyView.
Abstract Epilepsy syndromes are distinct electroclinical entities which have been recently defined by the International League Against Epilepsy Nosology and Definitions Task Force. Each syndrome is associated with “a characteristic cluster of clinical and EEG features, often supported by specific etiologic findings”.
Elaine C. Wirrell, Nicola Specchio, Rima Nabbout, Phillip L. Pearl, Kate Riney   +4 more
wiley   +1 more source

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod

Frontiers in Neurology, 2019
Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai, Keita Takahashi, Hiroyuki Abe, Yuichi Higashiyama, Hiroshi Doi, Hideyuki Takeuchi, Fumiaki Tanaka   +6 more
doaj   +1 more source

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. [PDF]

Eur J Neurol
This was a national multicenter comparative effectiveness research study using data from the Danish Multiple Sclerosis Registry. Relapsing–remitting multiple sclerosis patients initiating ocrelizumab or natalizumab between January 2018 to April 2023 were included.
Maersk-Moller C, Pontieri L, Stilund MLM, Christensen JR, Storr LK, Hansen V, Schäfer J, Weglewski A, Romani KQ, Jensen HB, Illes Z, Papp V, Sejbaek T, Poulsen MB, Kant M, Torring CW, Sellebjerg F, Magyari M, DMSG Group.   +18 more
europepmc   +2 more sources